107 related articles for article (PubMed ID: 28551924)
1. [ADHERENCE TO ORAL ANTI-CANCER DRUGS IN HEMATO-ONCOLOGY].
Ashkenazi S; Dreyer J; Raanani P; Leader A
Harefuah; 2017 Apr; 156(4):254-258. PubMed ID: 28551924
[TBL] [Abstract][Full Text] [Related]
2. Impact of oncology pharmacist-managed oral anticancer therapy in patients with chronic myelogenous leukemia.
Lam MS; Cheung N
J Oncol Pharm Pract; 2016 Dec; 22(6):741-748. PubMed ID: 26419691
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Evaluation of Adherence to Therapy, Its Associations, and Its Implications in Patients With Chronic Myeloid Leukemia Receiving Imatinib.
Unnikrishnan R; Veeraiah S; Mani S; Rajendranath R; Rajaraman S; Vidhubala Elangovan GS; Radhakrishnan V; Ganesan TS; Sagar TG; Ganesan P
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):366-371.e3. PubMed ID: 27052853
[TBL] [Abstract][Full Text] [Related]
4. The effectiveness of therapeutic patient education on adherence to oral anti-cancer medicines in adult cancer patients in ambulatory care settings: a systematic review.
Arthurs G; Simpson J; Brown A; Kyaw O; Shyrier S; Concert CM
JBI Database System Rev Implement Rep; 2015 Jun; 13(5):244-92. PubMed ID: 26455611
[TBL] [Abstract][Full Text] [Related]
5. [Anticancer drug adherence].
Despas F; Roche H; Laurent G
Bull Cancer; 2013 May; 100(5):473-84. PubMed ID: 23694959
[TBL] [Abstract][Full Text] [Related]
6. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia.
Darkow T; Henk HJ; Thomas SK; Feng W; Baladi JF; Goldberg GA; Hatfield A; Cortes J
Pharmacoeconomics; 2007; 25(6):481-96. PubMed ID: 17523753
[TBL] [Abstract][Full Text] [Related]
7. Lack of congruence between patients' and health professionals' perspectives of adherence to imatinib therapy in treatment of chronic myeloid leukemia: A qualitative study.
Wu S; Chee D; Ugalde A; Butow P; Seymour J; Schofield P
Palliat Support Care; 2015 Apr; 13(2):255-63. PubMed ID: 24524212
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
9. Patient adherence to oral anticancer drugs: an emerging issue in modern oncology.
Foulon V; Schöffski P; Wolter P
Acta Clin Belg; 2011; 66(2):85-96. PubMed ID: 21630604
[TBL] [Abstract][Full Text] [Related]
10. The value of open access and a patient centric approach to oral oncolytic utilization in the treatment of Chronic Myelogenous Leukemia: A U.S. perspective.
Das L; Gitlin M; Siegartel LR; Makenbaeva D
Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):133-140. PubMed ID: 28287008
[TBL] [Abstract][Full Text] [Related]
11. Good adherence to imatinib therapy among patients with chronic myeloid leukemia--a single-center observational study.
Jönsson S; Olsson B; Söderberg J; Wadenvik H
Ann Hematol; 2012 May; 91(5):679-685. PubMed ID: 22048790
[TBL] [Abstract][Full Text] [Related]
12. Factors Influencing Adherence in Cancer Patients Taking Oral Tyrosine Kinase Inhibitors: A Qualitative Study.
Verbrugghe M; Duprez V; Beeckman D; Grypdonck M; Quaghebeur M; Verschueren C; Verhaeghe S; Van Hecke A
Cancer Nurs; 2016; 39(2):153-62. PubMed ID: 25815430
[TBL] [Abstract][Full Text] [Related]
13. Adherence to targeted oral anticancer medications.
Geynisman DM; Wickersham KE
Discov Med; 2013 Apr; 15(83):231-41. PubMed ID: 23636140
[TBL] [Abstract][Full Text] [Related]
14. Improving adherence to oral cancer therapy in clinical practice.
McCue DA; Lohr LK; Pick AM
Pharmacotherapy; 2014 May; 34(5):481-94. PubMed ID: 24877187
[TBL] [Abstract][Full Text] [Related]
15. Assessing the need for improved strategies and medication-related education to increase adherence for oral anticancer medications in the young adult oncology population.
Divakaruni A; Saylor E; Duffy AP
J Oncol Pharm Pract; 2018 Jul; 24(5):337-342. PubMed ID: 28387636
[TBL] [Abstract][Full Text] [Related]
16. Patient perspectives on the barriers associated with medication adherence to oral chemotherapy.
Muluneh B; Deal A; Alexander MD; Keisler MD; Markey JM; Neal JM; Bernard S; Valgus J; Dressler LG
J Oncol Pharm Pract; 2018 Mar; 24(2):98-109. PubMed ID: 27895220
[TBL] [Abstract][Full Text] [Related]
17. Adherence to imatinib among patients attending Saskatchewan Cancer Agency Pharmacies.
Dicus M; Lyons B; Olson C; Tran DA; Blackburn DF
J Oncol Pharm Pract; 2015 Dec; 21(6):403-8. PubMed ID: 24903271
[TBL] [Abstract][Full Text] [Related]
18. Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed.
Eliasson L; Clifford S; Barber N; Marin D
Leuk Res; 2011 May; 35(5):626-30. PubMed ID: 21095002
[TBL] [Abstract][Full Text] [Related]
19. Factors influencing adherence in CML and ways to improvement: Results of a patient-driven survey of 2546 patients in 63 countries.
Geissler J; Sharf G; Bombaci F; Daban M; De Jong J; Gavin T; Pelouchova J; Dziwinski E; Hasford J; Hoffmann VS
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1167-1176. PubMed ID: 28289895
[TBL] [Abstract][Full Text] [Related]
20. A once-daily dasatinib dosing strategy for chronic myeloid leukemia.
Bryant G
Clin J Oncol Nurs; 2009 Jun; 13(3):316-23. PubMed ID: 19502190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
